Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

GSK Announces Depemokimab Late-Breaking Data Presented At ERS Show A 54% Reduction In Severe Asthma Exacerbations; SWIFT-1 And SWIFT-2 Phase III Data Show Depemokimab Delivered Significant And Clinically Meaningful Reduction In Exacerbations Over 52 Weeks Versus Placebo Plus Standard Of Care, In Duplicate Studies

Author: Benzinga Newsdesk | September 09, 2024 09:38am

Posted In: GSK